Combination of venetoclax with BCR-ABL tyrosine kinase inhibitor as a therapeutic strategy for Philadelphia chromosome-positive leukemias

Venetoclax has shown synergism with BCR-ABL1 tyrosine kinase inhibitors (TKIs) in preclinical studies for patients with Philadelphia chromosome-positive (Ph+) leukemias. This combination may suggest a novel treatment strategy for Ph + leukemias. We conducted a retrospective study to summarize the ac...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Hematology (Luxembourg) 2023-12, Vol.28 (1), p.2237790-2237790
Hauptverfasser:	Zou, Jing-Ying, Huang, Si-Man, Zhoub, Hai-Xia, Xu, Ming-Zhu, Sun, Ai-Ning, Wu, De-Pei, Xue, Sheng-Li, Zhang, Tong-Tong
Format:	Artikel
Sprache:	eng
Schlagworte:	combination of venetoclax with TKI efficacy Fusion Proteins, bcr-abl - genetics Humans hypomethylating agents Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Philadelphia Chromosome Philadelphia chromosome-positive leukemias Protein Kinase Inhibitors - therapeutic use Retrospective Studies Tyrosine Kinase Inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!